Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Seki

Showing results (301-310 of 304) with videos related to

Pageof 31
Sort By:
You have reached the last page of results.This site can display upto 304 results.
Oncogene|September 12, 2000
Identification and characterization of a 500-kb homozygously deleted region at 1p36.2-p36.3 in a neuroblastoma cell lineM Ohira, H Kageyama, M Mihara, et al.
Allergy|May 7, 2015
Novel scoring system and algorithm for classifying chronic rhinosinusitis: the JESREC StudyT Tokunaga, M Sakashita, T Haruna, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 15, 2016
Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)K Yamazaki, M Nagase, H Tamagawa, et al.
Science (New York, N.Y.)|October 25, 1996
A gene map of the human genomeG D Schuler, M S Boguski, E A Stewart, et al.
Pageof 31

Showing results (301-310 of 304) with videos related to

Sort By:
Pageof 31
You have reached the last page of results.This site can display upto 304 results.
Oncogene|September 12, 2000
Identification and characterization of a 500-kb homozygously deleted region at 1p36.2-p36.3 in a neuroblastoma cell lineM Ohira, H Kageyama, M Mihara, et al.
Allergy|May 7, 2015
Novel scoring system and algorithm for classifying chronic rhinosinusitis: the JESREC StudyT Tokunaga, M Sakashita, T Haruna, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 15, 2016
Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)K Yamazaki, M Nagase, H Tamagawa, et al.
Science (New York, N.Y.)|October 25, 1996
A gene map of the human genomeG D Schuler, M S Boguski, E A Stewart, et al.
Pageof 31